Last deal

$1.9M

Amount

Grant

Stage

17.08.2023

Date

5

all rounds

$2.2M

Total amount

General

About Company
Inherent Biosciences is a molecular diagnostics company revolutionizing trial and error medicine, restoring hope.

Industry

Sector :

Subsector :

Keywords :

Also Known As

Inherent

founded date

01.01.2019

Number of employees

Last funding type

Grant

IPO status

Private

Description

By leveraging epigenetics and detecting gene dysregulation, Inherent Biosciences develops innovative diagnostics and therapeutics for complex diseases like infertility, autoimmune disease, and autism. Their epigenetic platform pioneers a new category of tools that provide personal insights into biology, enabling doctors to guide patients effectively. With a focus on pain management, embryo quality, COVID-19, and more, Inherent Biosciences aims to transform the way we diagnose and treat complex diseases. Their first product, Path Fertility, addresses infertility issues and can be found at pathfertility.com.
Contacts